US equities |
MU $1,074.89 ▲+0.00% INTC $119.13 ▼-0.17% NVDA $233.95 ▲+0.00% META $728.08 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00% SPCX $158.96 ▲+0.00% PTC $144.03 ▲+0.00%
FinancialContent

Articles published by 23andMe Holding Co.

News headline image
23andMe to Report FY2023 Fourth Quarter and Full Year Financial Results
From 23andMe Holding Co.
Via GlobeNewswire
Tickers ME
News headline image
23andMe Releases New Report Revealing Likelihood of Developing Lupus
From 23andMe Holding Co.
Via GlobeNewswire
Tickers ME
News headline image
Reza Afkhami Joins 23andMe as Chief Corporate Development Officer
From 23andMe Holding Co.
Via GlobeNewswire
Tickers ME
News headline image
23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
From 23andMe Holding Co.
Via GlobeNewswire
Tickers ME
News headline image
Morehouse School of Medicine, Sickle Cell Foundation of Georgia and 23andMe Launch Sickle Cell Carrier Status Awareness Program
From 23andMe Holding Co.
Via GlobeNewswire
Tickers ME
News headline image
23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease
From 23andMe Holding Co.
Via GlobeNewswire
Tickers ME
News headline image
23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023
From 23andMe Holding Co.
Via GlobeNewswire
Tickers ME
News headline image
New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized Healthcare
From 23andMe Holding Co.
Via GlobeNewswire
Tickers ME
News headline image
23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies
From 23andMe Holding Co.
Via GlobeNewswire
Tickers ME
News headline image
23andMe to Present at Upcoming Investor Conferences
From 23andMe Holding Co.
Via GlobeNewswire
Tickers ME
News headline image
23andMe Reports FY2023 Third Quarter Financial Results
From 23andMe Holding Co.
Via GlobeNewswire
Tickers ME
News headline image
23andMe to Report FY2023 Third Quarter Financial Results
From 23andMe Holding Co.
Via GlobeNewswire
Tickers ME
News headline image
23andMe Survey Shows Majority of People Less Stressed About Their Health During This Holiday Season
From 23andMe Holding Co.
Via GlobeNewswire
Tickers ME
News headline image
23andMe Reports FY2023 Second Quarter Financial Results
From 23andMe Holding Co.
Via GlobeNewswire
Tickers ME
News headline image
23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting
From 23andMe Holding Co.
Via GlobeNewswire
Tickers ME
News headline image
23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for a Commonly Prescribed Cholesterol Medication
From 23andMe Holding Co.
Via GlobeNewswire
Tickers ME
News headline image
23andMe to Report FY2023 Second Quarter Financial Results
From 23andMe Holding Co.
Via GlobeNewswire
Tickers ME
News headline image
23andMe to Present at Upcoming Investor Conferences
From 23andMe Holding Co.
Via GlobeNewswire
Tickers ME
News headline image
23andMe Announces Trials-in-Progress Poster Presentation on 23ME-00610, An Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting
From 23andMe Holding Co.
Via GlobeNewswire
Tickers ME
News headline image
23andMe to Report FY2023 First Quarter Financial Results
From 23andMe Holding Co.
Via GlobeNewswire
Tickers ME